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Painful diabetic neuropathy (PDN) is a common complication of diabetes 
mellitus which hugely affect life routines and quality. We aimed to 
investigate the effects of minocycline and ifenprodil on nociceptive behavior 
response, oxidant-antioxidant status and pro-inflammatory markers level in 
the PDN rat’s spinal cord. Forty-eight male Sprague-Dawley rats were 
divided into six groups (n=8): non-diabetic control, diabetic PDN control, 
diabetic PDN rats received minocycline (80µg/day or 160µg/day) and 
diabetic PDN rats received ifenprodil (0.5µg/day or 1.0µg/day). Diabetes 
was induced by single injection of streptozotocin at 60mg/kg. The rats were 
allowed for two weeks period to develop into PDN condition. The 
intrathecal treatments were given for seven days period. The rat’s hind paw 
was then injected with 5% formalin to induce chronic inflammatory pain 
and sacrificed three days post-formalin injection. Spinal cord tissue was 
removed and homogenized (10% homogenate). ELISA for oxidant-
antioxidant markers (MDA, catalase and SOD) and pro-inflammatory 
markers (TNF-α and IL-1β) were carried out. The results showed that 
untreated PDN rats exhibited increased nociceptive behavior responses 
indicating hyperalgesia apart from increased MDA activity, reduced catalase 
with insignificant change in SOD enzymes activities, increased TNF-α and 
insignificant change in IL-1β level. Minocycline and ifenprodil suppressed 
MDA activity and improved catalase and SOD activities. Minocycline 
attenuated both pro-inflammatory cytokines whilst ifenprodil reduced TNF-
α level but increased IL-1β level. In conclusion, minocycline and ifenprodil 
showed potent anti-nociceptive, anti-oxidant and anti-inflammatory effects 
but possibly via different pathway and mechanism. 
 
Keywords: Painful diabetic neuropathy, minocycline, ifenprodil, formalin 
test, catalase, interleukin-1β, malondialdehyde, superoxide dismutase, 
tumour necrosis factor-α 
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INTRODUCTION 
 
Painful diabetic neuropathy (PDN) is a chronic pain that 
is developed due to abnormalities in the peripheral 
somatosensory system in the diabetic patient (Wang et 
al., 2014). The occurrence of PDN arises as a result of 
hyperglycemia-related with local metabolic and 
microvascular alterations in both type I and type II 
diabetes mellitus (DM) (Tesfaye et al., 2010, Wang et al., 
2014). According to the recent reports, approximately 
30% of DM patients develop PDN which can be manifes-
ted as spontaneous pain, allodynia (pain to normally 
innocuous stimuli) and hyperalgesia (increased perce-
ption of pain to noxious stimuli) (Tavakoli and Malik, 
2008). Long-term hyperglycemia in PDN decreases 
nerve functionality and nerve blood flow which result in 
malnourished nerve and leads to permanent nerve 
damage (Vinik and Mehrabyan, 2004). Besides that, 
diabetic neuropathy may also progressively result in the 
gradual decreasing in peripheral sensation and eventu-
ally complete loss of all sensations to heat, cold, press-
ure or pain, leading to amputation (Kline et al., 2003). 
 
Hyperglycemia is considered a major pathophysiological 
factor in the development of PDN, however, the mecha-
nisms are still not fully understood. Hyperglycemia has 
been reported to activate some major pathways like 
polyol pathway, advanced glycation end products (AGE), 
hexosamine flux, mitogen-activated protein kinase 
(MAPK), poly-ADP ribose polymerase (PARP) and cyclo-
oxygenase-2 (COX-2) activation. Cumulative effects of 
these cascade produce intense oxidative stress, cytokine 
release and neuroinflammation (Sandireddy et al., 
2014). Ongoing studies reported the important role of 
microglial activation and NR2B subunit of NMDA 
receptors activation in the pathogenesis of PDN and 
other types of neuropathic pain (Tsuda, 2016, Wang et 
al., 2011, Wang et al., 2014). However, the effects of 
minocycline and ifenprodil treatment on formalin-
induced chronic inflammatory pain, oxidant-antioxidant 
status and pro-inflammatory markers levels in the PDN 
rat model are still lacking and unclear.  
 
Minocycline is a semi-synthetic second-generation tetra-
cycline (Kraus et al., 2005, Mora et al., 2014) and has 
been reported to possess analgesic property via its 
capability on inhibiting microglial expression 
(Kobayashi et al., 2013, Tikka et al., 2001, Tikka and 
Koistinaho, 2001, Yrjänheikki et al., 1998). Kraus et al. 
(2005) have demonstrated that minocycline possesses 
anti-inflammatory effects via its action in reducing the 
inducible nitric oxide synthase, caspase-1 activity, 
metalloprotease activity and formation of cyclooxyge-
nase and prostaglandins. Moreover, other evidence 
showed the free-radical scavenging activities of mino-
cycline (Miyachi et al., 1986) on animal models of stroke 
and Parkinson’s disease (Gilgun-Sherki et al., 2002). 
Minocycline has also shown to suppress lipid peroxi-
dation in rat’s brain homogenate (Kraus et al., 2005), 
increase superoxide dismutase activity and reduced the 
levels of nitric oxide, hydrogen peroxide and malondi-
aldehyde in the mitochondrial cell of Drosophila flies 
treated with manganese (Mora et al., 2014).  
 
Ifenprodil is a non-competitive NMDA receptor of NR2B 
subunit antagonist. This drug is known for its 
stimulation of brain circulation and selectively inhibits 
NR2B-containing NMDA receptors (Suzuki et al., 1999). 
It has been reported to have minimal side effect profiles 
compared to another similar NMDA antagonists (Chizh 
et al., 2001). The previous study showed NR2B subunit 
protein has been found in the spinal cord (Boyce et al., 
1999), thus it may become one of the potential targets to 
combat PDN. Numerous studies have shown the 
analgesic effect of ifenprodil on neuropathic pain models 
(Chizh et al., 2001, Boyce et al., 1999, Zhang et al., 2009), 
but too limited studies have found the effect of 
ifenprodil to oxidative stress markers on neuropathic 
pain, specifically diabetic neuropathy. The present study 
aimed to determine the effects of microglial activation 
inhibitor (minocycline) and NMDA receptor NR2B 
subunit antagonist (ifenprodil) on nociceptive behavior 
responses induced by formalin, oxidant-antioxidant and 
pro-inflammatory markers levels in streptozotocin-
induced painful diabetic neuropathy rat model. We also 
aimed to find association of nociceptive behavior 
produced with oxidant-antioxidant status and levels of 
pro-inflammatory markers in the spinal cord of the rats. 
We hypothesized that both minocycline and ifenprodil 
may reduce the nociceptive behavior responses, 
oxidative stress and pro-inflammatory markers level in 
the spinal cord of streptozotocin-induced PDN rats. 
 
 
MATERIALS AND METHODS 
 
2.1 Animals 
All the procedures conducted on the rats have obtained 
the approval from Ethics Committee of Universiti Sains 
Malaysia Health Campus, Malaysia [USM/Animal Ethics 
Approval/2014 (91) (560)]. Forty-eight Sprague-
Dawley male rats (200-230 g, 8-10 weeks old) were 
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randomly assigned into six groups comprising of: (1) 
non-diabetic control (S+CB), (2) diabetic control rats 
that developed PDN (S+STZ), diabetic rats with PDN that 
received (3) minocycline hydrochloride (International 
Laboratory, USA) at a lower dose (M 80) or (4) 
minocycline hydrochloride at a higher dose (M 160), and 
diabetic rats with PDN that received (5) ifenprodil 
tartrate (International Laboratory, USA) at a lower dose 
(I 0.5) or (6) ifenprodil tartrate at a higher dose (I 1.0). 
All the rats were housed individually in an air-
conditioned room (20˚C) under 12 h light/dark cycles 
beginning at 7:00. They were fed with standard food 
pellets and free access to water and allowed for 
acclimatization in Animal Research and Service Centre 
(ARASC) for four days prior to experimentation. The rats 
were fasted for 14 hours prior to single dose injection of 
streptozotocin (60 mg/kg) to induce Type-I DM. 
Meanwhile, non-diabetic rats were injected with single 
dose injection of vehicle (citrate buffer pH 4.5). Ten 
percent sucrose solution was given to the rats for one-
day post-STZ injection to avoid hypoglycemia. The rats 
were allowed for two weeks period to develop into 
painful diabetic neuropathy condition. The selection of 
PDN rats was determined at two weeks post-STZ 
injection via tactile allodynia assessment (unpublished 
data). Only rats with 15% hyperalgesic from the 
baseline value were included in this study based on a 
method by Daulhac et al. (2006). 
 
2.2 Direct drug delivery 
Two weeks after diabetic induction, 20 µL of the 
treatment by either saline (vehicle), minocycline (80 
µg/day or 160 µg/day) or ifenprodil (0.5 µg/day or 1.0 
µg/day) was administered via direct intrathecal drug 
delivery method following Lu and Schmidtko (2013) for 
seven constitutive days. The rats were initially 
anaesthetized with the mixture of isoflurane and oxygen 
in 1:4 ratio using an anesthesia machine. The back of the 
rat’s body was shaved and the area between L5 and L6 
spinous processes were chosen as the site of skin 
puncture. The vertical puncture of the needle to the dura 
mater was confirmed by either a reflexive flick or the “S” 
formation of the rat’s tail. The treatment was slowly 
released and the rats were observed for two minutes 
after the injection to ensure no motor impairment in the 
rats. 
 
2.3 Formalin test 
The chronic inflammatory pain was induced by injecting 
5% formalin solution to the dorsal surface of the right 
hind paw. The rat was immediately transferred to a 
Plexiglas chamber (26 cm x 20 cm x 20 cm) and pain 
behavior responses were recorded for one hour and 
scored by two persons blinded to the treatment groups. 
A mirror was placed beneath the floor at a 45º angle to 
allow a clearer view of the injected paw. The pain 
behavior score assessed was based on the pain score 
from 0 to 3 referred to Dubuisson and Dennis (1978) as 
follows: 
 
0 = the foot flat on the floor with all toes splayed 
indicating rats having no pain 
1 = the injected paw has little or no weight on it with no 
toes splaying, indicating mild pain 
2 = the injected paw is lifted up and the paw is not in 
contact with any surface, indicating moderate pain 
3 = the injected paw is shaken, licked or bitten 
indicating severe pain 
 
The nociceptive behavior responses were tabulated for 
each minute and averaged at a 5-minute interval (Hayati 
et al., 2008). The nociceptive responses were divided 
into phase 1 (mean score from minute-0 to minute-5) 
and phase 2 (mean score from minute-15 to minute-60). 
 
2.4 Preparation of tissue samples 
The rats were sacrificed three days post-formalin 
injection by an overdose of sodium pentobarbitone and 
decapitated using a guillotine after the pinch reflex was 
not detected. In our unpublished work, activated 
microglia was demonstrated to be clearly expressed and 
localized to the portion of lamina I-IV in the spinal cord 
at three days after formalin injection, which is also 
supported by Fu et al. (1999). The lumbar enlargement 
region of the spinal cord tissue was then removed and 
homogenized using a tissue homogenizer. The 10% 
homogenate of the spinal cord tissue was centrifuged at 
10,000 x g for 10 minutes at 4˚C to discard nuclei and 
cell debris. The supernatant was collected and stored at 
-80˚C until further assay. 
 
2.5 Oxidant-antioxidant Assays 
 
2.5.1 Malondialdehyde (MDA) 
The concentration of MDA in the spinal cord sample was 
measured by the thiobarbituric acid (TBA) test by 
commercially available MDA assay kit (Northwest Life 
Science Specialties, Canada). The reaction of MDA with 
TBA, forming an MDA-TBA2 adduct that absorbs 
strongly at 532 nm wavelength. Butylated 
hydroxytoluene (BHT) was initially added into an 
Eppendorf tube, followed by the addition of the sample. 
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Acid Reagent was then added to the tube followed by 
TBA Reagent. The mixture was then vigorously mixed 
and incubated at 60˚C for 60 minutes. The mixture was 
then centrifuged at 10,000 x g for 3 minutes at 4 ˚C. The 
reaction mixture was then transferred to a cuvette and 
the absorbance of the sample was measured by a 
spectrophotometer (PG Instruments, UK) from 400 to 
700 nm. The highest peak of the sample was detected at 
532 nm wavelength. The sample was then transferred 
into a 96-wells flat-bottom microplate and the MDA 
reaction was measured at 532 nm using an automated 
ELISA reader (Thermofisher Scientific, USA) to perform 
a third derivative analysis. The results were expressed 
as mmol thiobarbituric acid reactive substances per mg 
protein. 
 
2.5.2 Catalase 
Catalase catalyzes the breakdown of hydrogen peroxide 
(H2O2) to produce water and molecular oxygen. Catalase 
activity of the spinal cord sample was determined by 
using a commercial ELISA kit (Bioassays, USA). H2O2 
substrate was added to the samples in 96-wells plate 
and incubated for 30 minutes at room temperature. 
Detection Reagent was then added to the mixture and 
re-incubated for 10 minutes at room temperature before 
the absorbance of an H202 reaction was read at 570 nm 
wavelength by an ELISA reader. The specific activity of 
catalase was calculated and expressed in terms of unit U 
per mg of protein (U/mg protein). 
 
2.5.3 Superoxide Dismutase (SOD) 
Superoxide dismutase (SOD) catalyzes the dismutation 
of superoxide into oxygen and hydrogen peroxide. This 
enzyme is an important antioxidant defense in all cells 
exposed to O2. The reaction of the SOD in the spinal cord 
sample was determined using a commercially available 
kit (Abnova, Taiwan). Working Reagent (Xanthine, WST-
1) was firstly added into 96-wells flat-bottom 
microplate containing samples. XO enzyme was then 
added immediately and the reaction was measured at 
440 nm using an ELISA reader (ODo). The mixture was 
then incubated at room temperature for 60 minutes in 
the dark and again measured at the similar wavelength 
(OD60). The reaction of SOD (OD60-OD0) was calculated 
and expressed as U per mg protein. 
 
2.5.4 Protein measurement 
Protein concentration in the spinal cord sample was 
determined by the method of Bicinchoninic Acid using 
bovine serum albumin as a standard. 
 
2.6  Assays of pro-inflammatory markers 
 
2.6.1 Interleukin-1β (IL-1β) 
Interleukin-1β level of the spinal cord homogenate was 
determined by using a commercially available ELISA kit 
(Cusabio, China). The sample was added to the IL-1β 
readily coated -96 wells flat-bottom microplate and 
incubated for two hours at 37˚C. The sample was then 
completely removed and Biotin-antibody (1x) was 
added to the wells and re-incubated at 37˚C for one 
hour. The microplate was again re-incubated for 15 
minutes at 37˚C in the dark. The reaction was stopped 
by adding Stop solution and measured with an 
automated ELISA reader at 450 nm wavelength. 
 
2.6.2 Tumor Necrosis Factor-α (TNF-α) 
TNF-α concentration in spinal cord tissue was 
determined by using a commercially available ELISA 
assay kit (Raybiotech, USA). Samples were initially 
added to the TNF-α-readily coated-96 wells flat-bottom 
microplate and incubated for 2.5 hours at room 
temperature. The sample was then discarded and the 
wells were washed with 1X Wash Solution. 1X prepared 
biotinylated antibody was then added into each well and 
re-incubated for 1 hour at room temperature. The 
solution was then discarded and the plate was re-
washed. Streptavidin solution was then added to each 
well and incubated for 45 minutes at room temperature. 
The plate was again washed before TMB One-Step 
Substrate reagent was added to each well and incubated 
for 30 minutes at room temperature in the dark. The 
reaction was stopped with the addition of Stop Solution 
and immediately read at 450 nm wavelength using an 
automated ELISA reader.  
 
2.7 Statistical analysis 
The data for each parameter were initially checked for 
the data distribution. Phase 1 and 2 of formalin test, 
MDA level, SOD and catalase enzymes activities, IL-1β 
and TNF-α levels were analyzed with one-way ANOVA 
with either post-hoc LSD (sphericity assumed) or 
Dunnett’s T3 (sphericity not assumed), according to the 
value of Levene’s test. The correlations between phases 
of formalin test with oxidant-antioxidant (MDA, catalase 
and SOD activities) as well as pro-inflammatory 
cytokines (IL-1β and TNF-α) levels in this study were 
assessed by Pearson’s correlation analysis. The values 
were expressed as the mean ± standard error of the 
mean (S.E.M). The significance level was taken as less 
than 0.05 (p < 0.05). 
. 
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RESULTS AND DISCUSSION 
 
3.1 Effect of minocycline and ifenprodil on 
nociceptive behavior score 
All the rats challenged with an intraplantar injection of 
formalin demonstrated biphasic response 
characteristics with phase 1 and phase 2 separated by a 
quiescent period (Figure 1A). The result showed a 
significant increase in the burst activity of nociceptive 
behavior during phase 1 (Figure 1B) but no significantly 
differed during phase 2 in (S+STZ) group compared to 
(S+CB) group (Figure 1C). Minocycline administration of 
both doses was shown to significantly reduced formalin-
induced nociceptive behavior in both phase 1 (Figure 
1B) and phase 2 (Figure 1C) compared to (S+STZ) and 
(S+CB) groups. At the same time, the reduction of 
nociceptive behavior responses was obvious compared 
to ifenprodil-treated groups. Meanwhile, ifenprodil 
treatment at both doses did not alter nociceptive 
behavior score during phase 1 (Figure 1B) but 
significantly reduced nociceptive behavior score during 
phase 2 (Figure 1C). 
 
3.2 Effect of minocycline and ifenprodil on 
malondialdehyde (MDA) activity 
MDA activity was significantly increased in diabetic PDN 
control (S+STZ) compared to (S+CB) group. This 
suggests that painful diabetic neuropathy causes lipid 
peroxidation in the spinal cord. Interestingly, the 
increased lipid peroxidation level in PDN rat’s spinal 
cord was shown to be corrected by minocycline and 
ifenprodil at both lower and higher doses (Figure 2). 
 
 
  
Figure 1 (A) Figure 1 (B) 
 
 
 
Figure 1 (A): Nociceptive behavior responses for all groups 
in one- Figure 1 (A): hour period. The values are expressed 
as mean ± S.E.M (n=8). 
 
Figure 1 (B): Nociceptive behavior response during phase 
1. The values are expressed as mean ± S.E.M (n=8). *, p<0.05 
Significant compared to (S+CB) groups, #, p<0.001 
significant compared to (S+STZ), (S+CB), (I 0.5) and (I 1.0) 
groups, and €€, p<0.001 significant compared to (S+STZ), 
(S+CB), (I 0.5) and (I 1.0) groups. 
 
Figure 1 (C): Nociceptive behavior response during phase 2. 
The values are expressed as mean ± S.E.M (n=8). #, p<0.05 
significant compared to (I 1.0) group, ##, p<0.001 
significant compared to (S+STZ), (S+CB) and (I 0.5) groups, 
€€, p<0.001 significant compared to (S+STZ), (S+CB), (I 0.5) 
and (I 1.0) groups, §,p<0.05 significant compared to (S+STZ) 
group, §§, p<0.001 significant compared to (S+CB) group, ¥, 
p<0.05 significant compared to (S+STZ) and ¥¥, p<0.001 
significant effect compared to (S+CB) group. 
 
Figure 1 (C) 
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Figure 2 Figure 3 
 
  
Figure 4 Figure 5 
 
Figure 2: Malonylaldehyde (MDA) activity between the groups. The values are expressed as mean ± S.E.M (n=8). *, 
p<0.001 significant compared to (S+CB) group, ##, p<0.001 significant compared to (S+STZ) and (S+CB) groups, €€, 
p<0.001 significant compared to (S+STZ) and (S+CB) groups, §§, p<0.001 significant compared to (S+STZ) and (S+CB) 
groups and ¥¥, p<0.001 significant compared to (S+STZ) and (S+CB) groups. 
 
Figure 3: Catalase level between the groups. The data was expressed as mean ± SEM (n=8). *, p<0.05 significant 
compared to (S+CB) group, ##, p<0.001 significant compared to (S+STZ) and (I 0.5) groups, €€, p<0.001 significant 
compared to (S+STZ), (S+CB), (M 80), (I 0.5) and (I 1.0) groups, and ¥, p<0.05 significant compared to (S+STZ) group. 
 
Figure 4: Superoxide dismutase (SOD) activity between the groups. The values are expressed as mean ± S.E.M (n=8). 
#, p<0.05 significant compared to (S+STZ) group, €, p<0.05 significant compared to (S+STZ) group, €€, p<0.001 
significant compared to (S+CB) group, §, p<0.05 significant compared to (S+STZ) group, §§, p<0.001 significant 
compared to (S+CB) group, ¥¥, p<0.001 significant compared to (S+STZ), (S+CB), (M 80), (M 160) and (I 0.5) groups. 
 
Figure 5 : Interleukin-1β (IL-1β) level between the groups. The values were express as mean ± S.E.M (n=8). #, p<0.05 
significant compared to (S+STZ) and (S+CB) groups, §, p<0.05 significant compared to (S+STZ) and (S+CB) groups, §§, 
p<0.001 significant compared to (M 80) and (M 160) groups, ¥, p<0.05 significant compared to (S+STZ) and (S+CB) 
groups, ¥¥, p<0.001 significant compared to (M 80) and (M 160) groups. 
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3.3 Effect of Minocycline and Ifenprodil on Catalase 
activity 
Catalase enzyme activity was found to be significantly 
reduced in (S+STZ) group compared to (S+CB) group. 
The reduced catalase activity in PDN rats was improved 
by minocycline treatment at both doses with the higher 
administration of minocycline (160 µg/day) was highly 
boosted catalase enzyme activity to scavenge lipid 
peroxidation. Meanwhile, the administration of 
ifenprodil at a higher dose (1.0 µg/day) was 
demonstrated to increase catalase enzyme activity in the 
spinal cord of PDN rats whilst the use of ifenprodil at a 
lower dose (0.5 µg/day) did not give any significant 
effect on catalase enzyme activity (Figure 3). 
 
3.4 Effect of Minocycline and Ifenprodil on 
Superoxide dismutase activity 
The reduction of SOD enzyme activity in diabetic PDN 
control (S+STZ) group was demonstrated to be not 
significantly differed with (S+CB) group. The treatment 
of minocycline at both doses has been shown to boost 
SOD enzyme activity in the spinal cord of PDN rats. 
Meanwhile, the administration of ifenprodil at both 
doses also significantly boost SOD enzyme activity with 
the higher dose of ifenprodil (1.0 µg/day) highly 
boosted SOD enzyme activity in PDN rat’s spinal cord. 
The increase in SOD enzyme activity was also seen to be 
better in the ifenprodil-treated group at higher dose 
compared to minocycline-treated groups (Figure 4). 
 
3.5 PRO-INFLAMMATORY MARKERS 
 
3.5.1Effects of Minocycline and Ifenprodil on 
interleukin-1β level 
The increase in pro-inflammatory IL-1β level in diabetic 
PDN control (S+STZ) group was not significantly 
differed from (S+CB) group. The treatment with 
minocycline at a higher dose (160 µg/day) was 
significantly reduced the level of IL-1β whilst the 
treatment of minocycline at a lower dose did not give 
effect to IL-1β level. On the other hand, the treatment of 
ifenprodil at both doses has been exhibited to 
significantly increase the release of IL-1β in the spinal 
cord of PDN rats (Figure 5). 
 
3.5.2 Minocycline and Ifenprodil reduce TNF-α level 
The pro-inflammatory TNF-α level was significantly 
increased in diabetic PDN control (S+STZ) group 
compared to (S+CB) group. Minocycline and ifenprodil 
treatments at both doses have been shown to 
significantly reduced the level of TNF-α in the spinal 
cord of PDN rats in which not statistically differed from 
(S+CB) group (Figure 6). 
 
 
  
Figure 6 Figure 7 
 
Figure 6: Tumor necrosis factor-α (TNF-α) level between the groups. The values were express as mean ± S.E.M 
(n=8). *, p<0.05 significant compared to (S+CB) group, #, p<0.05 significant compared to (S+STZ) and (S+CB) groups, 
€, p<0.05 significant compared to (M 80) group, €€, p<0.001 significant compared to (S+STZ) group, §§, p<0.001 
significant compared to (S+STZ) group and ¥¥, p<0.001 significant compared to (S+STZ) group. 
 
Figure 7: Relationship between nociceptive behavior response and SOD enzyme activity (r = -0.516, p<0.001). 
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3.6 Relationship between nociceptive behavior 
score and SOD enzyme activity 
A Pearson product-moment correlation was run to 
determine the relationship between phase 2 of formalin 
test and SOD enzyme activity. There were a strong, 
negative correlations detected between SOD (r=-0.516, 
n=48, p<0.001) and phase 2 of pain behavior score 
(Figure 7). No significant correlation was detected 
between catalase enzyme activity, MDA, IL-1β and TNF-
α level with phases of the formalin test. 
 
 
DISCUSSION 
 
In the present study, we have explored the effect of 
minocycline (microglial inhibitor) and ifenprodil (NR2B 
subunit of NMDA receptor antagonist) on the 
development of painful diabetic neuropathy. The 
assessment of hypersensitivity to chemical-induced 
nociception was performed by formalin test. The results 
of this study demonstrate that (1) minocycline and 
ifenprodil treatments attenuated the development of 
painful diabetic neuropathy (2) that possibly associated 
with the reduced levels of pro-inflammatory cytokine(s) 
and oxidative stress as well as increased antioxidant 
enzymes. This study also supports the fact that (3) NR2B 
subunit contributes to the increased hypersensitivity 
and spinal microglia becomes activated in painful 
diabetic neuropathy which further leads to the 
increased release of pro-inflammatory mediators and 
oxidative stress. 
 
In formalin test, phase 1 of nociceptive responses 
actually represents acute nociceptive pain in which the 
burst of nociceptive responses is due to the peripheral 
action as inflammatory mediators released irritate 
peripheral nerves and tissues after the formalin 
injection. Whereas, phase 2 of nociceptive responses 
reflects the combination of on-going inflammatory-
associated afferent input from the peripheral nerves and 
tissues as well as functional modifications in the dorsal 
horn of the spinal cord (Pabreja et al., 2011). In other 
words, phase 2 represents the central actions after 
formalin injection. In the present study, PDN rats 
demonstrated exacerbated responses in phase 1 but not 
phase 2, proving the peripheral nerves of PDN rats are 
still functioning although previous studies reported the 
damage in peripheral nerves of diabetic rats (Jirmanova, 
1993). Minocycline was found to attenuate the 
nociceptive responses during phase 1 and phase 2 
indicating that minocycline may act peripherally and 
centrally in attenuating nociceptive processes. 
Meanwhile, ifenprodil has been shown to attenuate 
nociceptive responses during phase 2 but not phase 1 of 
the formalin test. It indicates that the action of ifenprodil 
possibly at centrally in diabetic neuropathy rats model. 
Although NR2B subunit is also expressed on small and 
medium sized-primary afferent terminals (Ma and 
Hargreaves, 2000), however, it is possible that the 
expression may be reduced due to the effects of diabetic 
neuropathy on peripheral nerves. The metabolic 
changes promote demyelination and remyelination 
processes of peripheral nerves (Pabreja et al., 2011) in 
which progressively enhance the pathogenesis of 
diabetic neuropathy. These processes may reduce the 
expression of NR2B subunit of NMDA receptors on the 
peripheral nerve of PDN rats. NR2B subunit of NMDA 
receptors has been found to be denser and more defined 
distribution in the spinal dorsal horn laminae than other 
members of NR2 family, therefore the inhibition effect of 
ifenprodil may be more prominently seen in the spinal 
level. 
 
As previously mentioned, the imbalance between ROS 
and antioxidant enzymes and production of oxidative 
stress has been associated with the occurrence of 
diabetic related complications. In the present study, we 
found a marked elevated MDA activity and the 
prominent reduction in catalase enzyme activity in 
diabetic PDN rats which are parallel to the previous 
investigations (Ates et al., 2006, Ates et al., 2007, Delibas 
et al., 2004, Koneri et al., 2014, Montilla et al., 1998, 
Pabreja et al., 2011, Qujeq et al., 2004, Zhao et al., 2014). 
However, the reduction in SOD enzyme activity in 
diabetic PDN was not significantly differed from non-
diabetic rats. In fact, the previous studies revealed that 
SOD enzyme activity is quite erratic and demonstrated 
an irregular pattern in the occurrence of diabetes. The 
amount of SOD enzyme was found to be inconsistently 
increased, no change and reduced in certain fluids, 
tissues and organs of STZ-induced diabetic models (El-
Khatib et al., 2001, Jang et al., 2000, Kȩdziora-
Kornatowska et al., 1998, Mohan and Das, 1998, 
Obrosova et al., 2000, van Dam et al., 1998). The altered 
oxidant-antioxidant balance by the increased oxidant 
MDA activity and reduced catalase and SOD enzymes 
activities explains the less protection of antioxidant 
enzymes the spinal cord of diabetic PDN rats. The higher 
the free radicals produced, the lower the antioxidant 
defense protecting the affected cells and tissues from 
severe oxidative damage (Saini et al., 2007). The 
treatment with minocycline and ifenprodil has 
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successfully protected the spinal cord of PDN rats by 
improving the oxidant-antioxidant balance. Both of 
these treatments attenuated lipid peroxidation and 
boosted catalase and SOD enzymes activities in the 
spinal cord of PDN rats. Minocycline has been reported 
to possess anti-oxidant effect and highly potential to 
capture free radicals (Dean et al., 2012, Mora et al., 
2014). The antioxidant activity of minocycline has also 
been shown in previous studies on various animal 
models of neuropathic pain (Aras et al., 2013, Kriz et al., 
2003, Pabreja et al., 2011). The inhibition of microglial 
activation by minocycline proves that activated 
microglia in CNS is a major source of free radicals in 
painful diabetic neuropathy (Pabreja et al., 2011, Tsuda 
et al., 2008). The protection of minocycline by improving 
the oxidant-antioxidant balance may explain the 
attenuation of nociceptive behavior responses during 
phase 1 and 2 of the formalin test. Furthermore, the 
strong correlation of SOD enzyme activity with formalin-
induced nociceptive responses also strengthen this 
effect. Moreover, the attenuation of lipid peroxidation by 
ifenprodil may strongly support that activated NR2B 
subunit of NMDA receptors contributes to the formation 
of oxidative stress in painful diabetic neuropathy model 
(Hu et al., 2015, Zhu et al., 2015). Although there is a 
very limited study that has investigated the effect of 
NMDA receptor NR2B subunit antagonists like 
ifenprodil on the oxidative damage, we believe that 
ifenprodil may have some potential effects on the 
pathways that boost the anti-oxidation enzymes 
production and activity, thus causes the significant 
suppression of lipid peroxidation in spinal cord tissue. 
   
It is also well-known that diabetic neuropathic pain 
relies on the level of pro-inflammatory release. Hence, in 
this study we have investigated the markers of pro-
inflammatory cytokines to gain the insight into 
antinociceptive, antioxidant and anti-inflammatory 
effects of minocycline and ifenprodil. Several clinical 
investigations have reported that diabetic neuropathy is 
related with the increased pro-inflammatory mediators 
(Pabreja et al., 2011, Skundric and Lisak, 2003). Most 
importantly, the source of pro-inflammatory cytokines 
in the spinal cord is derived from activated microglia 
and the release of these cytokines may activate NR2B 
receptor of NMDA receptors. The TNF-α expression has 
been demonstrated to induce the phosphorylation of c-
Jun N-terminal kinase 1 and stimulates NF-κB leading to 
the release of chemokine ligand 2 (CCL2). CCL2 may 
then acts on C-C chemokine receptor type 2 (CCR2) on 
neurons and communicate positively with neuronal 
NMDA receptors and α-amino-2-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors to produce 
central sensitization and synaptic plasticity (Sun et al., 
2015).  The release of these inflammatory cytokines and 
free radicals may then directly activate microglia 
(Pabreja et al., 2011, Tangpong et al., 2008). Marchand 
et al. (2009) suggested that the production of TNF-α 
seems to be dependent on microglial activation since 
these cytokines are produced by many types of cells 
during inflammation including microglial cells (Stirling 
et al., 2005). Both TNF-α and IL-1β may enhance 
membrane K+ ion conductance in a non-voltage-gated 
fashion which leads to neuronal hyperexcitability 
(Leung and Cahill, 2010) therefore leading to persistent 
central sensitization. Moreover, these cytokines may 
also enhance their productions from glial cells as well as 
another cell type(s) (Pabreja et al., 2011) after the 
release. Persistent with the previous studies, we also 
observed the obvious increase in TNF-α with the 
increase of IL-1β level although not statistically different 
from the non-diabetic group. The release of pro-
inflammatory mediators may also contribute to the 
accumulation of free radicals as demonstrated by the 
increased lipid peroxidation (MDA) in the spinal cord of 
diabetic PDN rats in this study. The increased of these 
cytokines was markedly inhibited by minocycline 
treatment, similarly reported by the previous studies 
(Krady et al., 2005, Pabreja et al., 2011, Raghavendra et 
al., 2003). Apart from that, ifenprodil demonstrated a 
dramatic attenuation of TNF-α level dose-dependently. 
In fact, there is limited research investigating the effect 
of ifenprodil on pro-inflammatory markers, but the 
present study showed ifenprodil enhances the 
production of IL-1β level in the spinal cord of the PDN 
rats. Although the IL-1β release is implicated in the 
phosphorylation of NR2B subunit of NMDA receptor in 
normal rats, it is unclear how ifenprodil could cause the 
increased level of IL-1β. It is assumed that ifenprodil 
may also affect another mechanism or signaling 
pathway that may affect other cells to be activated, 
therefore increase the release of IL-1β. There is not a 
single study that has explored the effect of ifenprodil on 
astroglia and oligodendrocytes in neuropathic pain 
model. It is possible although not yet determined that 
ifenprodil may affect these cells to exaggeratively 
release pro-inflammatory cytokines (Noguchi, 2010, 
Vela et al., 2002). However, further investigation should 
be carried out to confirm the aforementioned 
mechanism. 
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CONCLUSION 
 
The results demonstrated that both minocycline and 
ifenprodil attenuates the development of painful 
diabetic neuropathy by attenuating formalin-induced 
nociceptive responses, improve oxidant-antioxidant 
balance and reduced pro-inflammatory marker(s) level 
in streptozotocin-model of painful diabetic neuropathy. 
Further studies are required to identify this specific 
mechanism that may be involved in the inhibition by 
both minocycline and ifenprodil on the pathogenesis of 
painful diabetic neuropathy. 
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